Valuation: Cosmos Holdings Inc.

Market Cap 3.83Cr 3.36Cr 3.17Cr 2.89Cr 5.41Cr 367.18Cr 5.45Cr 38Cr 15Cr 186.87Cr 14Cr 14Cr 608.11Cr P/E 2026 *
-1.81x
P/E 2027 * 5.43x
Enterprise Value 3.83Cr 3.36Cr 3.17Cr 2.89Cr 5.41Cr 367.18Cr 5.45Cr 38Cr 15Cr 186.87Cr 14Cr 14Cr 608.11Cr EV / Sales 2026 *
0.47x
EV / Sales 2027 * 0.35x
Free-Float
76.24%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 26/02/2016
Director of Finance/CFO 43 11/11/2020
Chief Operating Officer 56 01/02/2023
Director TitleAgeSince
Director/Board Member 58 13/01/2014
Chairman 60 26/02/2016
Director/Board Member 59 18/11/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 3.83Cr
-1.27%-1.16%+14.30%+98.19% 10TCr
+0.61%-1.64%+44.02%+150.25% 5.15TCr
-0.39%+0.78%-14.33%+267.14% 2.08TCr
-0.25%-0.87%-11.20%-10.55% 793.36Cr
-1.66%-0.34%-38.67%-34.93% 680.43Cr
+2.80%+5.40%-1.23%+15.38% 652.4Cr
-0.20%-0.93%-19.00%-33.12% 593.28Cr
+0.33%+1.41%-2.13%+20.63% 494.52Cr
+1.25%+8.76%+20.44%+22.78% 401.98Cr
Average -0.44%+0.72%-0.87%+55.08% 2.33TCr
Weighted average by Cap. -0.45%-0.32%+14.39%+109.75%

Financials

2026 *2027 *
Net sales 8.08Cr 7.11Cr 6.7Cr 6.11Cr 11Cr 775.62Cr 12Cr 80Cr 31Cr 394.75Cr 30Cr 30Cr 1.28TCr 11Cr 9.75Cr 9.19Cr 8.38Cr 16Cr 1.06TCr 16Cr 110.25Cr 43Cr 541.31Cr 42Cr 41Cr 1.76TCr
Net income - -
Net Debt - -
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-

Quarterly revenue - Rate of surprise